National Institute of Allergy and Infectious Diseases Seeks Partner for Eosinophil-Derived Neutralizing Agent (EDNA) to Treat Respiratory Syncytical Virus and Parainfluenza Virus Infections

Summary

The National Institute of Allergy and Infectious Diseases (NIAID) is seeking a partner to develop an eosinophil-derived neutralizing agent (EDNA) to treat severe respiratory infections in children and the elderly caused by respiratory syncytical virus (RSV) and parainfluenza virus (PIV), with the potential to impact over 100,000 hospitalizations annually in the U.S.